Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.
Stefan A J BuckC Louwrens BraalMaaike M HofmanEsther Oomen-de HoopPeter de BruijnInge M Ghobadi Moghaddam-HelmantelKoen G A M HussaartsMijntje B VastbinderQuirine C van Rossum-SchornagelRon H N van SchaikAgnes JagerStijn L W KoolenRon H J MathijssenPublished in: Therapeutic advances in medical oncology (2022)
Probenecid resulted in a clinically relevant increase of endoxifen concentrations in breast cancer patients treated with adjuvant tamoxifen. This combination therapy could provide a solution for patients with a CYP2D6-poor metabolizer phenotype or endoxifen concentrations below the threshold despite earlier tamoxifen dose.